EvolutionaryScale

Research on the record

• 2024-06-25EvolutionaryScale's ESM3 protein model writes a green fluorescent protein only 58% identical to any known one, and in the lab it glows about as brightly as natural GFPLevel 4 · Tested in the physical world

Graded by how far the evidence went, not how good the result is. See the methodology.

Read on AI4S.fyi

• 2026-10-20A World Model of Life: Biohub’s Alex Rives on Virtual Cells, Measurement and the $1.8B Data PushCommentaryAlex Rives, with Nathan Labenz · The Cognitive Revolution
• 2026-03-23Designing AI for Disruptive ScienceCommentaryAlvin Djajadikerta · Asimov Press

Also on the timeline

• 2025-11-06EvolutionaryScale, the team behind the ESM3 protein model, joins Chan Zuckerberg's BiohubOrganizations

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2024-06-25Seed · more than $142 millionconfirmedLed by Nat Friedman, Daniel Gross, Lux Capital · With Amazon, NVentures (NVIDIA)Stated use: expand the capabilities of its models

Each round links to its line on the funding record, with its source.

Also in Protein design on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-28BioGeometrySeries A+ · not disclosed; the A series to date tops $100MBuilds generative models for biology: GeoFlow, an all-atom model that predicts the structures of proteins and their complexes and designs binders, and GeoCell, a virtual-cell model of how cells' gene expression responds to genetic and drug perturbations. An automated lab expresses and tests the designs and feeds the data back. It designs antibodies, vaccines, peptides and enzymes for partners and its own pipeline, including synthetic-biology products.
• 2026-09-24BigHat BiosciencesSeries C · $75MDesigns antibodies with machine learning tied to a fast automated wet lab (Milliner) that makes and tests designs; its lead drug BHB810 is in the clinic.
• 2026-08-11Aureka BiotechnologiesSeries B · $100MDesigns antibodies with its own biological foundation model, AuraIDE (released in open form as OpenDDE), trained and retrained on data from its own single-cell functional screens.
• 2026-07-14Chai DiscoverySeries C · $400MBuilds AI models that predict how molecules bind and design antibodies from scratch, and licenses them to drugmakers as software.
• 2026-06-17MoleculeMindSeries A (extension) · A-series cumulative total over US$100 millionAI protein structure prediction and design (MoleculeOS, MMFold, MMDesign) sold to drugmakers and industrial-enzyme users, with a few in-house early programs.
• 2026-03-20Helixon (Earendil Labs)Round (unnamed) · $787MAI protein modelling plus high-throughput experiments to design antibodies, especially bispecifics, which it licenses to Sanofi and Genentech and develops in-house.

All 15 in this field →